Correlation Between Inmed Pharmaceuticals and CRISPR Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Inmed Pharmaceuticals and CRISPR Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inmed Pharmaceuticals and CRISPR Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inmed Pharmaceuticals and CRISPR Therapeutics AG, you can compare the effects of market volatilities on Inmed Pharmaceuticals and CRISPR Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inmed Pharmaceuticals with a short position of CRISPR Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inmed Pharmaceuticals and CRISPR Therapeutics.

Diversification Opportunities for Inmed Pharmaceuticals and CRISPR Therapeutics

0.31
  Correlation Coefficient

Weak diversification

The 3 months correlation between Inmed and CRISPR is 0.31. Overlapping area represents the amount of risk that can be diversified away by holding Inmed Pharmaceuticals and CRISPR Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CRISPR Therapeutics and Inmed Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inmed Pharmaceuticals are associated (or correlated) with CRISPR Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CRISPR Therapeutics has no effect on the direction of Inmed Pharmaceuticals i.e., Inmed Pharmaceuticals and CRISPR Therapeutics go up and down completely randomly.

Pair Corralation between Inmed Pharmaceuticals and CRISPR Therapeutics

Considering the 90-day investment horizon Inmed Pharmaceuticals is expected to generate 4.37 times more return on investment than CRISPR Therapeutics. However, Inmed Pharmaceuticals is 4.37 times more volatile than CRISPR Therapeutics AG. It trades about -0.01 of its potential returns per unit of risk. CRISPR Therapeutics AG is currently generating about -0.07 per unit of risk. If you would invest  988.00  in Inmed Pharmaceuticals on July 2, 2022 and sell it today you would lose (414.00)  from holding Inmed Pharmaceuticals or give up 41.9% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy97.73%
ValuesDaily Returns

Inmed Pharmaceuticals  vs.  CRISPR Therapeutics AG

 Performance (%) 
       Timeline  
Inmed Pharmaceuticals 
Inmed Performance
0 of 100
Over the last 90 days Inmed Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively steady which may send shares a bit higher in October 2022. The new chaos may also be a sign of medium-term up-swing for the company stakeholders.

Inmed Price Channel

CRISPR Therapeutics 
CRISPR Performance
0 of 100
Over the last 90 days CRISPR Therapeutics AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, CRISPR Therapeutics is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the insiders.

CRISPR Price Channel

Inmed Pharmaceuticals and CRISPR Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Inmed Pharmaceuticals and CRISPR Therapeutics

The main advantage of trading using opposite Inmed Pharmaceuticals and CRISPR Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inmed Pharmaceuticals position performs unexpectedly, CRISPR Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will offset losses from the drop in CRISPR Therapeutics' long position.
Inmed Pharmaceuticals vs. AIR CANADA
Inmed Pharmaceuticals vs. Frontier Group Holdings
Inmed Pharmaceuticals vs. All Nippon Airways
Inmed Pharmaceuticals vs. International Consol
The idea behind Inmed Pharmaceuticals and CRISPR Therapeutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
CRISPR Therapeutics vs. Bristol-Myers Squibb
CRISPR Therapeutics vs. Bio-Rad Laboratories
CRISPR Therapeutics vs. Amgen Inc
CRISPR Therapeutics vs. Amerisourcebergen Corp
Check out your portfolio center. Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Other Complementary Tools

Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go